The thesis

Medpace runs clinical trials for drugmakers chasing the GLP-1 and metabolic health boom, placing it in the contract research layer of that trade. Revenue grew 8.5% last year and net margin sits at 18.2%, solid operations but not boom economics. The stock trades at 37.1x earnings while analysts consensus says hold, and our score of 29 keeps it on the watchlist. The tension is plain: the metabolic narrative promises acceleration, the numbers show a single-digit grower priced for far more.

Why now

GLP-1 pipeline expansion is feeding trial volume into contract research organizations just as Medpace's 8.5% growth shows no visible acceleration yet. The gap between theme enthusiasm and reported results is widest exactly here, making the next quarterly booking numbers the deciding evidence.

What to watch

Watch new backlog and booking trends in the next two quarterly reports for evidence GLP-1 demand is converting into contracted revenue. Watch gross margin against the 29.1% baseline and any change in the hold consensus after earnings.

Key risks

At 37.1x earnings with 8.5% growth, any multiple compression toward growth rates hits hard. Trial results and insurance coverage decisions in metabolic drugs can swing order flow sharply in either direction. AGLP-1 slowdown or client budget cuts would expose the premium valuation.

Theme exposure